Metropolis Healthcare Ltd. (IN:METROPOLIS)
:METROPOLIS
METROPOLIS Stock Chart & Stats
₹1929.70
-₹8.50(-0.42%)
At close: 4:00 PM EST
₹1929.70
-₹8.50(-0.42%)
Day’s Range― - ―
52-Week Range₹345.92 - ₹564.82
Previous CloseN/A
Volume139.28K
Average Volume (3M)3.90K
Market Cap
₹87.69B
Enterprise Value₹90.30B
Total Cash (Recent Filing)₹1.18B
Total Debt (Recent Filing)₹0.00
Price to Earnings (P/E)60.4
Beta0.69
Next Earnings
May 26, 2026EPS Estimate
2.68Next Dividend Ex-DateN/A
Dividend Yield0.21%
Share Statistics
EPS (TTM)2.31
Shares Outstanding207,327,770
10 Day Avg. Volume4,604
30 Day Avg. Volume3,901
Financial Highlights & Ratios
PEG Ratio4.05
Price to Book (P/B)5.90
Price to Sales (P/S)5.90
P/FCF Ratio35.81
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)12.56
Revenue Forecast (FY)₹18.73B
Bulls Say, Bears Say
Bulls Say
Strong Balance SheetA very high equity ratio and low debt-to-equity give Metropolis durable financial flexibility. Low leverage reduces refinancing and interest-rate risk, enabling sustained capex for lab expansion, M&A optionality, and the ability to weather demand shocks without diluting shareholders.
Robust Cash GenerationStrong operating cash conversion and positive free cash flow growth support long-term reinvestment in centralized labs, technology, and patient collection networks. Reliable cash generation reduces dependence on external financing and underpins steady capital allocation and expansion.
High Margins And ProfitabilityVery high gross margins reflect low variable costs and pricing power in diagnostics; healthy EBITDA and improving net margins indicate scalable operations and cost discipline. Margin strength supports reinvestment in specialized testing and long-term earnings resilience.
Bears Say
Moderate Return On EquityROE around 10.9% is modest given the company's capital-light diagnostics model and low leverage. This suggests limited efficiency in converting equity into higher shareholder returns, which could constrain long-term per-share value unless operational productivity or pricing power improves.
Revenue Model Dependence On Fee-for-serviceHeavy reliance on transactional fee-for-service volumes and franchisee/collection economics exposes margins to pricing pressure and commission payouts. Growth depends on sustained patient flows and referrals, requiring ongoing brand investment and channel management to avoid margin erosion.
Modest EPS GrowthEPS growth near 9% is positive but modest relative to sector growth expectations; it signals limited operating leverage or pricing headroom. If revenue acceleration stalls, EPS growth may remain constrained, limiting long-term improvement in profitability per share.
Metropolis Healthcare Ltd. News
METROPOLIS FAQ
What was Metropolis Healthcare Ltd.’s price range in the past 12 months?
Metropolis Healthcare Ltd. lowest stock price was ₹345.92 and its highest was ₹564.82 in the past 12 months.
What is Metropolis Healthcare Ltd.’s market cap?
Metropolis Healthcare Ltd.’s market cap is ₹87.69B.
When is Metropolis Healthcare Ltd.’s upcoming earnings report date?
Metropolis Healthcare Ltd.’s upcoming earnings report date is May 26, 2026 which is in 50 days.
How were Metropolis Healthcare Ltd.’s earnings last quarter?
Metropolis Healthcare Ltd. released its earnings results on Feb 04, 2026. The company reported ₹2.312 earnings per share for the quarter, beating the consensus estimate of ₹2.235 by ₹0.077.
Is Metropolis Healthcare Ltd. overvalued?
According to Wall Street analysts Metropolis Healthcare Ltd.’s price is currently Overvalued.
Does Metropolis Healthcare Ltd. pay dividends?
Metropolis Healthcare Ltd. pays a Annually dividend of ₹4 which represents an annual dividend yield of 0.21%. See more information on Metropolis Healthcare Ltd. dividends here
What is Metropolis Healthcare Ltd.’s EPS estimate?
Metropolis Healthcare Ltd.’s EPS estimate is 2.68.
How many shares outstanding does Metropolis Healthcare Ltd. have?
Metropolis Healthcare Ltd. has 207,327,770 shares outstanding.
What happened to Metropolis Healthcare Ltd.’s price movement after its last earnings report?
Metropolis Healthcare Ltd. reported an EPS of ₹2.312 in its last earnings report, beating expectations of ₹2.235. Following the earnings report the stock price went down -0.474%.
Which hedge fund is a major shareholder of Metropolis Healthcare Ltd.?
Currently, no hedge funds are holding shares in IN:METROPOLIS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Metropolis Healthcare Ltd.
Metropolis Healthcare Limited provides diagnostic services in India. It offers clinical laboratory testing, and profiles and support services. The company provides diagnostic services for oncology, neurology, gynecology, and nephrology, as well as various health check-up packages for men, women, senior citizens, and youth and corporates. Its tests and profiles are used for prediction, early detection, diagnostic screening, confirmation, and/or monitoring of the disease. The company also offers corporate wellness and hospital laboratory solutions, as well as clinical research services. As of March 31, 2022, it operated 171 clinical laboratories, 9,000 pick-up points, and 704 assisted referral centers. The company was founded in 1980 and is headquartered in Mumbai, India.
Technical Analysis
HealthCare Global Enterprises Ltd.
―
Krsnaa Diagnostics Limited
―
Dr. Lal PathLabs Limited
―
Thyrocare Technologies Ltd
―
Vijaya Diagnostic Centre Ltd.
―